echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Literature sharing: Which is safer for the treatment of rheumatoid arthritis, JAK inhibitor or tumor necrosis factor inhibitor?

    Literature sharing: Which is safer for the treatment of rheumatoid arthritis, JAK inhibitor or tumor necrosis factor inhibitor?

    • Last Update: 2022-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background and purpose

    Biologic anti-rheumatic drugs (bDMARDs) have been the dominant model
    for the treatment of rheumatoid arthritis (RA) since 2010.
    The safety of tumor necrosis factor inhibitors (TNF inhibitors) and Janus kinase inhibitors (JAK inhibitors) in patients with RA is of concern
    .
    Studies aimed to evaluate the safety of
    JAK inhibitors and TNF inhibitors in patients with RA.

    method

    The study included patients diagnosed with RA between 2015 and 2017 in the Taiwan Health Insurance Research Database and followed up until 2018
    .
    Propensity score stability weighting was used to balance baseline characteristics
    in the JAK inhibitor and TNF inhibitor groups.
    To compare the incidence of safety endpoints between study groups, namely cardiovascular (CV) events, tuberculosis (TB), total hip replacement (THR), total knee replacement (TKR), and all-cause mortality
    .

    outcome

    1.
    A total of 3179 RA patients treated with JAK inhibitors (n=822) and TNF inhibitors (n=2357) were included, and the average follow-up time of JAK inhibitor group was 2.
    02 years and that of TNF inhibitor group was 2.
    10 years;

    2.
    The incidence of all-cause death was the highest, followed by TKR, THR, CV events and TB;

    3.
    The incidence of safety endpoints in the JAK inhibitor group was lower than that in the TNF inhibitor group, but there was no significant difference (p->0.
    05).

    conclusion

    In real-world RA patients, there was no significant difference
    in safety profile and mortality between JAK inhibitors and TNF inhibitors.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.